PaulaD.RyanMD

PubMed

• 8 citations
  Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community...
  Gregory L Price, Lavanya Sudharshan, Paula Ryan, Jonathan Rajkumar, Kristin M Sheffield, Emily Nash Smyth, Claudia Morato Guimaraes, Sarah Rybowski, Gebra Cuyun Carter...> ;Current Medical Research and Opinion. 2022 Aug 1
• Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple negative breast and serous ovarian cancers.
  Birkbak, N. J.,Li, Y.,Pathania, S.,Greene-Colozzi, A.,Dreze, M.,Bowman-Colin, C.,Sztupinszki, Z.,Krzystanek, M.,Diossy, M.,Tung, N.,Ryan, P. D.,Garber, J. E.,Silver, D...> ;Ann. Oncol.. 2018 Feb 17
• 590 citations
  Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
  Melinda L. Telli, Kirsten Timms, Julia Reid, Bryan T. Hennessy, Gordon B. Mills, Kristin C. Jensen, Zoltan Szallasi, William T. Barry, Eric P. Winer, Nadine Tung, Stev...> ;Clinical Cancer Research. 2016 Aug 1
• 289 citations
  TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
  Steven J. Isakoff, Erica L. Mayer, Lei He, Tiffany A. Traina, Lisa A. Carey, Karen Krag, Hope S. Rugo, Minetta C. Liu, Vered Stearns, Steven E. Come, Kirsten Timms, An...> ;Journal of Clinical Oncology. 2015 Apr 6
• 17 citations
  Multifocal and multicentric breast cancer is associated with increased local recurrence regardless of surgery type
  Talha Shaikh, Tiffany Tam, Tianyu Li, Shelly B. Hayes, Lori J. Goldstein, Richard J. Bleicher, Marcia Boraas, Elin R. Sigurdson, Paula D. Ryan, Penny R. Anderson> ;The Breast Journal. 2015 Mar 1
• 5 citations
  Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy
  Yanin Chavarri-Guerra, Michaela J. Higgins, Jackie Szymonifka, Tessa Cigler, P Liedke, Ann H. Partridge, Jennifer A. Ligibel, Steven E. Come, Dianne M. Finkelstein, Pa...> ;British Journal of Cancer. 2014 Nov 25
• 125 citations
  Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
  Judith Balmaña, Nadine Tung, Steven J. Isakoff, Begoña Graña, Paula D. Ryan, Cristina Saura, E.S. Lowe, P. Frewer, Eric P. Winer, José Baselga, Judy Garber> ;Annals of Oncology. 2014 May 14
• Intermittent letrozole therapy for metastatic breast cancer: case reports and literature review.
  Lei Fan, Pedro E.R. Liedke, Steven J. Isakoff, Jessica St. Louis, Paula D. Ryan, Paul E. Goss> ;Clinical Breast Cancer. 2014 Apr 1
• 40 citations
  Young adult daughters of BRCA1/2 positive mothers: What do they know about hereditary cancer and how much do they worry?†
  Andrea Farkas Patenaude, Nadine Tung, Paula D. Ryan, Leif W. Ellisen, Larissa Hewitt, Katherine A. Schneider, Kenneth P. Tercyak, Julie Aldridge, Judy Garber> ;Psycho-Oncology. 2013 Sep 1
• 5 citations
  Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy.
  Rimoun Boutrus, Rita Abi Raad, Irene Kuter, Marek Ancukiewicz, Lisa Roberts, Natalie A. Solomon, Taylor Ngo, Heather Borick, Paula D. Ryan, Beverly Moy, Michele A. Gad...> ;The International Journal of Biological Markers. 2013 Apr 23
• 53 citations
  Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers
  Jessica Chubiz, Janie M. Lee, Michael E. Gilmore, Chung Yin Kong, Kathryn P. Lowry, Elkan F. Halpern, Pamela M. McMahon, Paula D. Ryan, G. Scott Gazelle> ;Cancer. 2013 Mar 15
• 18 citations
  Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location.
  Angela Jain, Paula D. Ryan, Michael V. Seiden> ;Journal of the National Comprehensive Cancer Network. 2012 Sep 1
• 1 citations
  Faciocutaneous cancer syndromes: spot the diagnosis.
  Patrick J. Morrison, Paula D. Ryan> ;The Oncologist. 2012 Jul 1
• 71 citations
  Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.
  Kathryn P. Lowry, Janie M. Lee, Chung Yin Kong, Pamela M. McMahon, Michael E. Gilmore, Jessica Chubiz, Etta D. Pisano, Constantine Gatsonis, Paula D. Ryan, Elissa M. O...> ;Cancer. 2012 Apr 15
• 385 citations
  Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
  Nicolai Juul Birkbak, Zhigang C. Wang, Ji Young Kim, Aron Charles Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J. Dirk Igleh...> ;Cancer Discovery. 2012 Apr 1
• 4 citations
  Which individuals undergoing BRACAnalysis need BART testing
  Kristen M. Shannon, Linda H Rodgers, Gayun Chan-Smutko, Devanshi Patel, Michele Gabree, Paula D. Ryan> ;Cancer Genetics. 2011 Aug 1
• A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive ...
  Higgins MJ, Gabrail NY, Miller K, Agresta SV, Sharma S, McDonagh C, Murray J, Andreas K, Frye S, Moyo VM, Niyikiza C, Ryan PD> ;J. Clin. Oncol.. 2011-05-20
• A phase II clinical trial of drug withdrawal in women with progressive breast cancer while on aromatase inhibitor therapy.
  Cigler T, Higgins MJ, Szymonifka J, Partridge AH, Ligibel JA, Finkelstein D, Come SE, Ryan PD, Goss PE> ;J. Clin. Oncol.. 2011-05-20
• TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.
  Isakoff SJ, Goss PE, Mayer EL, Traina TA, Carey LA, Krag K, Rugo HS, Liu MC, Stearns V, Come SE, Borger DR, Quadrino CA, Finkelstein D, Garber JE, Ryan PD, Winer EP, E...> ;J. Clin. Oncol.. 2011-05-20
• 27 citations
  Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery
  Mehra Golshan, Judy Garber, Rebecca Gelman, Nadine Tung, Barbara L. Smith, Susan Troyan, Caprice C. Greenberg, Eric P. Winer, Paula D. Ryan> ;Annals of Surgical Oncology. 2011 Mar 1
• 62 citations
  Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers
  Kasmintan A. Schrader, Serena Masciari, Niki Boyd, Clara Salamanca, Janine Senz, Darren N. Saunders, Erika Yorida, Sarah Maines-Bandiera, Pardeep Kaurah, Nadine Tung, ...> ;Journal of Medical Genetics. 2011 Jan 1
• 31 citations
  Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1 -associated breast cancers
  Nadine Tung, Alexander Miron, Stuart J. Schnitt, Shiva Gautam, Katharina Fetten, Jennifer Kaplan, Yosuf Yassin, Ayodele Buraimoh, Ji Young Kim, Attila Marcell Szász, R...> ;Breast Cancer Research. 2010 Nov 16
• 710 citations
  Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
  Daniel P. Silver, Andrea L. Richardson, Aron Charles Eklund, Zhigang C. Wang, Zoltan Szallasi, Qiyuan Li, Nicolai Ytterdal Juul, Chee-Onn Leong, Diana Calogrias, Ayode...> ;Journal of Clinical Oncology. 2010 Mar 1
• 73 citations
  Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
  Nadine Tung, Yihong Wang, Laura C. Collins, Jennifer Kaplan, Hailun Li, Rebecca Gelman, Amy Comander, Bridget Gallagher, Katharina Fetten, Karen Krag, Kathryn A. Stoec...> ;Breast Cancer Research. 2010 Feb 11
• 49 citations
  Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers
  Janie M. Lee, Pamela M. McMahon, Chung Yin Kong, Daniel B. Kopans, Paula D. Ryan, Elissa M. Ozanne, Elkan F. Halpern, G. Scott Gazelle> ;Radiology. 2010 Feb 8
• Join now to see all